Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company plans to pursue apparel business restructuring, the launch of environmentally responsive new products in the functional solutions business, and the expanded sales, development and launch of new products, and other initiatives in the medical business. No reason for the revision from the previous forecast is provided.
Business structure improvement expenses of ¥3,311 million, consisting of losses associated with the consolidation and reorganization of production and logistics sites in the apparel business and the implementation of an early retirement program, among other items. Total extraordinary losses were ¥4,528 million. The impairment loss of ¥1,118 million reported in the segment information is included in business structure improvement expenses.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥132,000 million（+0.8%） |
| Operating profit | Not disclosed → ¥8,800 million（+80.3%） |
| Ordinary income | Not disclosed → ¥8,400 million（+70.7%） |
| Profit attributable to owners of the parent | Not disclosed → ¥5,200 million（+921.6%） |
| Net income per share | Not disclosed → 165.9 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue ¥130,918 million, operating profit ¥4,882 million, ordinary profit ¥4,920 million, profit attributable to owners of the parent ¥509 million, and earnings per share ¥15.83 (fiscal year ended March 2026) |
| Reason for the revision | The company plans to pursue apparel business restructuring, the launch of environmentally responsive new products in the functional solutions business, and the expanded sales, development and launch of new products, and other initiatives in the medical business. No reason for the revision from the previous forecast is provided. |
| Details and amount of extraordinary loss | Business structure improvement expenses of ¥3,311 million, consisting of losses associated with the consolidation and reorganization of production and logistics sites in the apparel business and the implementation of an early retirement program, among other items. Total extraordinary losses were ¥4,528 million. The impairment loss of ¥1,118 million reported in the segment information is included in business structure improvement expenses. |
| Dividend forecast revision | For the fiscal year ending March 2027, the company forecasts a dividend of ¥216 per share, comprising an ordinary dividend of ¥147 and a special dividend of ¥69. Whether the dividend forecast has been revised is not specified. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined in the fiscal year ended March 2026 due to the impact of the electronic components business, which was discontinued at the end of the previous fiscal year, lower overseas sales of plastic films, and a decline in existing apparel sales channels. Profit was affected by an inventory valuation write-down in the apparel business, sluggish sales in China and higher fixed costs in the medical business, and business structure improvement expenses in the apparel business. For the fiscal year ending March 2027, the company plans to pursue initiatives including apparel business restructuring, the launch of new products in the functional solutions business, and expanded sales in the medical business.